biotech – Page 4

Newswire

[ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
[ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
[ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
[ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers
[ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
[ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
[ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers
[ January 30, 2025 ] Alpha Modus (NASDAQ: AMOD) Secures 9th AI Patent, Strengthening Leadership in Retail Innovation Newsmakers
[ January 29, 2025 ] NEWTON GOLF Company (NASDAQ: SPGC) Provides Preliminary Financial Results for Fourth Quarter 2024 and Full Year 2024 Newsmakers
[ January 28, 2025 ] NanoVibronix (NASDAQ: NAOV)Advances Development of PainShield and UroShield with Completion of NextGen Prototypes Newsmakers

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin Comments Off

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral […]

Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin Comments Off

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

FSD Pharma, Inc (CSE: HUGE) (OTC: FSDDF) Building world’s largest indoor cannabis grower.

November 13, 2018 admin Comments Off

FSD Pharma, Inc (CSE: HUGE) (OTC: FSDDF) CEO Interview with Dr. Raza Bokhari. FSD Pharma is building the worlds largest licensed indoor cannabis growing facility […]

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin Comments Off

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative. Investor Presentation Deck

Healthcare

Pulmatrix (NASDAQ: PULM) Investor Presentation

October 8, 2018 admin Comments Off

Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018

The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies

July 16, 2018 admin Comments Off

Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing

Check-Cap (NASDAQ: CHEK) Announces Pricing of $17.5 Million Upsized Underwritten Public Offering

May 5, 2018 admin Comments Off

ISFIYA, Israel, May 04, 2018 — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, […]

Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

April 20, 2018 admin Comments Off

NEW YORK and CLEVELAND, April 20, 2018 – Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European […]